Intuitive Surgical Inc ISRG
We take great care to ensure that the data presented and summarized in this overview for INTUITIVE SURGICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ISRG
View all-
Vanguard Group Inc Valley Forge, PA30.9MShares$12.2 Billion0.25% of portfolio
-
Black Rock Inc. New York, NY30.3MShares$12 Billion0.29% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD16.5MShares$6.55 Billion0.81% of portfolio
-
State Street Corp Boston, MA15.1MShares$6 Billion0.27% of portfolio
-
Capital World Investors Los Angeles, CA7.28MShares$2.89 Billion0.5% of portfolio
-
Geode Capital Management, LLC Boston, MA7.15MShares$2.83 Billion0.27% of portfolio
-
Jpmorgan Chase & CO New York, NY6.73MShares$2.67 Billion0.24% of portfolio
-
Alliancebernstein L.P. New York, NY6.6MShares$2.62 Billion0.96% of portfolio
-
Morgan Stanley New York, NY5.28MShares$2.09 Billion0.17% of portfolio
-
Ken Fisher Fisher Asset Management, LLC | Camas, Wa4.57MShares$1.81 Billion0.86% of portfolio
Latest Institutional Activity in ISRG
Top Purchases
Top Sells
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Insider Transactions at ISRG
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Open market or private sale
|
Direct |
63
-17.6%
|
$24,948
$396.19 P/Share
|
|
May 17
2024
|
David J. Rosa President |
SELL
Bona fide gift
|
Direct |
2,507
-1.15%
|
-
|
|
May 16
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Open market or private sale
|
Direct |
175
-32.83%
|
$69,650
$398.28 P/Share
|
|
May 16
2024
|
Brian Edward Miller EVP & Chief Digital Officer |
SELL
Open market or private sale
|
Direct |
2,553
-20.97%
|
$1,021,200
$400.0 P/Share
|
|
May 15
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Open market or private sale
|
Direct |
175
-24.72%
|
$67,725
$387.22 P/Share
|
|
May 14
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Open market or private sale
|
Direct |
175
-19.82%
|
$66,500
$380.85 P/Share
|
|
May 13
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Open market or private sale
|
Direct |
175
-16.54%
|
$68,075
$389.16 P/Share
|
|
May 13
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
284
-2.48%
|
$110,476
$389.16 P/Share
|
|
May 13
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
90
+1.53%
|
$16,110
$179.7 P/Share
|
|
May 11
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Payment of exercise price or tax liability
|
Direct |
167
-2.85%
|
$64,462
$386.7 P/Share
|
|
May 11
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
360
+5.78%
|
-
|
|
May 10
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
239
-2.12%
|
$92,015
$385.55 P/Share
|
|
May 10
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
239
+2.08%
|
$63,813
$267.03 P/Share
|
|
May 03
2024
|
Mark J Rubash Director |
SELL
Open market or private sale
|
Direct |
1,709
-9.62%
|
$649,420
$380.0 P/Share
|
|
May 03
2024
|
Mark J Rubash Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,709
+8.78%
|
$504,155
$295.92 P/Share
|
|
Apr 29
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
376
-3.3%
|
$141,000
$375.39 P/Share
|
|
Apr 29
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
376
+3.2%
|
$93,624
$249.61 P/Share
|
|
Apr 26
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
1,498
-3.7%
|
$552,762
$369.09 P/Share
|
|
Apr 26
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
1,498
+3.53%
|
$386,484
$258.0 P/Share
|
|
Apr 25
2024
|
Mark J Rubash Director |
BUY
Exercise of conversion of derivative security
|
Direct |
569
+3.42%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 557K shares |
|---|
| Open market or private sale | 407K shares |
|---|---|
| Payment of exercise price or tax liability | 28.6K shares |
| Bona fide gift | 22.6K shares |